X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this agreement, Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market.
Lead Product(s): Liraglutide
Therapeutic Area: Endocrinology Product Name: Saxenda-Generic
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 06, 2023
Details:
Ketamine is a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia diagnostic and surgical procedures typically in combination with a muscle relaxant.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
Lead Product(s): Eptifibatide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Amoxicillin oral suspension is one of the most commonly prescribed antibiotics for children for the treatment of particular bacterial infections. Amoxicillin represents the first product that Juno will successfully import to address drug shortages through this division.
Lead Product(s): Amoxicillin Trihydrate
Therapeutic Area: Infections and Infectious Diseases Product Name: Amoxicillin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Juno intends to use these proceeds to expand its complex and high-value generic and biosimilar portfolio including Adrenaline Aguettant. Signet will further enhance Juno’s already strong growth profile given their extensive experience in pharma, and specifically with generics.
Lead Product(s): Epinephrine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Adrenaline Aguettant-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Signet
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
